This author has yet to write their bio.Meanwhile lets just say that we are proud Andrew Humphreys contributed a whooping 356 entries.
Gilead Sciences and South San Francisco-based Second Genome forged a four-year strategic collaboration worth more than $1.5 billion that will boost chances to discover and develop new targets and drug candidates for the treatment of inflammatory bowel disease through microbiome research.
ETHOS Health Communications, a Pennsylvania-based medical communications agency specializing in interpreting and communicating the innovative science and data for cutting-edge therapies, announced a name change to PRECISIONscientia.
New York is nearing a plateau in the number of coronavirus patients hospitalized, a sign of optimism even though the number of the deaths in the state hit a single-day high, Governor Andrew Cuomo said.
The World Health Organization has no blanket recommendation for countries and regions for easing measures to slow the spread of the coronavirus pandemic, but urged them not to lift them too early, a spokesman said.
Menlo Therapeutics, based in Bridgewater, New Jersey, released topline results from two Phase III trials of once daily oral serlopitant for pruritus (itching) associated with prurigo nodularis; neither trial met their primary endpoint.
Incyte presented the first Phase III data for ruxolitinib cream in atopic dermatitis. The research was presented at the Revolutionizing Atopic Dermatitis Virtual Symposium.
Following close on the heels of the company’s vaccine development agreement with China’s Xiamen Innovax Biotech, GlaxoSmithKline forged a research and development deal with Vir Biotechnology to develop treatments for COVID-19.
Morris Plains, New Jersey-based Immunomedics halted the company’s Phase III confirmatory ASCENT clinical trial of sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC).
The United States entered what an official called the “peak death week” of the coronavirus on Monday while a watchdog report said hospitals were struggling to maintain and expand capacity to care for infected patients.
One of the promising experimental drugs being tested to treat COVID-19, the disease caused by the novel coronavirus SARS-Cov2-, is Gilead Sciences’ remdesivir. The company had decided to accelerate production of the drug based on overwhelming demand.